DOCSLIB.ORG

2020 Annual Report HIGHLIGHTS SHAREHOLDER MANAGEMENT SUSTAINABILITY CORPORATE COMPENSATION FINANCIAL APPENDIX LETTER COMMENTARY REPORT GOVERNANCE REPORT REPORT 2

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2020 Annual Report HIGHLIGHTS SHAREHOLDER MANAGEMENT SUSTAINABILITY CORPORATE COMPENSATION FINANCIAL APPENDIX LETTER COMMENTARY REPORT GOVERNANCE REPORT REPORT 2 2020 Annual Report HIGHLIGHTS SHAREHOLDER MANAGEMENT SUSTAINABILITY CORPORATE COMPENSATION FINANCIAL APPENDIX LETTER COMMENTARY REPORT GOVERNANCE REPORT REPORT 2 CONTENTS #TogetherStrong Highlights 3 #TogetherStrong is a tag-name that covers #TogetherStrong aptly describes how we countless initiatives we took to address progressed through and emerged from this Letter to shareholders 7 pressing needs in the dental community extraordinary year. Management commentary 11 in 2020. Straumann Group in brief 12 Strategy in action 17 #TogetherStrong is forward-looking; it Products, solutions and services 21 It started with a website offering scientific expresses purpose, teamwork, courage, Innovation 26 and practical information to help Markets 29 determination, perseverance, moving Business performance (Group) 35 customers and staff through the corona forward and succeeding in turbulent Business performance (Regions) 38 virus crisis. Soon it became a holistic, Business performance (Financials) 44 surroundings – themes that are captured Share performance 46 omni-channel response including a in the pictures and contents of this report. Risk management 49 massive education platform. Sustainability report 57 The #TogetherStrong concept has Corporate governance 80 extended to thousands of activities Compensation report 107 and millions of communications. It demonstrates how the events of 2020 Financial report 123 fuelled our resourcefulness, innovation Appendix 184 and passion for creating opportunities. Global Reporting Initiative (GRI) 185 GRI content index 189 Points to note 193 2020 Annual Report Straumann’s Annual Reports for online users Straumann Group Straumann http://annualreport.straumann.com HIGHLIGHTS SHAREHOLDER MANAGEMENT SUSTAINABILITY CORPORATE COMPENSATION FINANCIAL APPENDIX LETTER COMMENTARY REPORT GOVERNANCE REPORT REPORT 3 HIGHLIGHTS Group key figures High staff engagement in CHF million score (4 pts above global 2020 2019 Change (%) Revenue in CHF benchmark) Revenue 1 426 1 596 −11 Gross profit 1 030 1 200 −14 Core 1 1 038 1 207 −14 1.4bn 78 EBITDA 406 481 −16 Core 1 421 505 −17 Operating profit (EBIT) 157 387 −59 Core 1 333 432 −23 CHF cash from operating Investment in staff learning Net profit 92 308 −70 activities ≈ 2019 level in CHF Core 1 261 338 −23 Cash generated from operating activities 377 378 0 Capital expenditure 82 150 −45 377m >3m Free cash flow 295 230 28 Basic EPS (in CHF) 5.75 19.33 −70 Core 1 16.20 21.21 −24 Employees (at year end) 7 340 7 590 −3 Oil and solvent Notes to core figures Core EBIT margin consumption 1 To facilitate a like-for-like comparison of the underlying business performance the Group presents ‘core’ results in addition to the results reported under IFRS. A detailed explanation and reconciliation is provided on p. 124 ff. of the Financial Report. 23% –8% 2020 Annual Report Gross profit in CHF Greenhouse gas emissions Straumann Group Straumann >1bn –2% HIGHLIGHTS SHAREHOLDER MANAGEMENT SUSTAINABILITY CORPORATE COMPENSATION FINANCIAL APPENDIX LETTER COMMENTARY REPORT GOVERNANCE REPORT REPORT 4 Revenue (more on p. 35 ff.) Operating and net profit (more onp. 36 ff.) Cash flow and investments (more onp. 36 ff.) Return (more on p. 45 ff.) in CHF million in CHF million in CHF million in % 5-year CAGR: 12% in CHF (14% organic growth) 500 400 60 350 50 400 1500 300 40 300 250 1000 200 30 200 150 20 500 100 100 10 50 0 0 0 0 2016 2017 2018 2019 2020 20161 20171 20182 20192 20202 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 Reported revenue Operating prot (EBIT) Operating cash ow Return on equity (ROE) Net prot Capital expenditure Return on capital employed (ROCE) 1 Excluding exceptionals Acquisitions & participations 2 Core 5y organic revenue Core EBIT in CHF Invested over 5y Free cash flow growth (CAGR) in the future in CHF margin 2020 Annual Report 14% 333m >1bn 21% Straumann Group Straumann HIGHLIGHTS SHAREHOLDER MANAGEMENT SUSTAINABILITY CORPORATE COMPENSATION FINANCIAL APPENDIX LETTER COMMENTARY REPORT GOVERNANCE REPORT REPORT 5 Performance by region By year-end, organic growth had returned to all regions. Being the least heavily affected, APAC rebounded to high-teen growth in Q4 to complete the year almost in line with 2019. EMEA and North America reported mid-single digit declines, while Latin America had to overcome the biggest challenge and achieved Europe, Middle 85% of its prior year organic revenue. East, Africa Change in CHF Revenue in CHF −8% Change organic North America Change in CHF −7% −10% Revenue in CHF 615m Change organic −5% 432m Asia/Pacific Change in CHF −5% Revenue in CHF Change organic Latin America −1% 2020 Annual Report Annual 2020 Change in CHF 289m Revenue in CHF −35% Change organic −15% Straumann Group Straumann 90m HIGHLIGHTS SHAREHOLDER MANAGEMENT SUSTAINABILITY CORPORATE COMPENSATION FINANCIAL APPENDIX LETTER COMMENTARY REPORT GOVERNANCE REPORT REPORT 6 Share information Relative share price development Total shareholder return Total in CHF in % shareholder return 1200 80 70 60 9.4% 1000 50 40 800 30 20 10 600 Market capitalization 0 –10 in CHF –20 400 2016 2017 2018 2019 2020 Straumann 16.4bn SMIM Total Return Index 200 2016 2017 2018 2019 2020 StraumannSwiss Mid Cap index (SMIM) adjusted STOXX® Europe 600 index (in CHF) adjusted Dividend per share in CHF Share information Details about share performance 3 in CHF on p. 46 ff. 5.75 2020 2019 2018 2017 2016 Earnings per share (EPS) 16.201 21.20 1 18.16 1 15.13 2 11.94 2 Ordinary dividend per share 5.753 5.75 5.25 4.75 4.25 2020 Annual Report Payout ratio 36%1 27% 1 29% 1 31% 2 36% 2 Share price at year end 1031.50 950.40 618.00 688.50 397.50 Share price 1 Based on core results. performance 2 Based on results excluding exceptionals. 3 Payable in April 2021 subject to shareholder approval. Straumann Group Straumann 8.5% HIGHLIGHTS SHAREHOLDER MANAGEMENT SUSTAINABILITY CORPORATE COMPENSATION FINANCIAL APPENDIX LETTER COMMENTARY REPORT GOVERNANCE REPORT REPORT 7 Dear Shareholder, As a company we have learned, innovated, adapted, relinquished, matured and persevered in 2020. Above all, we have understood the value of bringing and keeping people, ideas and things together when traditional approaches are no longer possible. This is why #TogetherStrong aptly describes how we progressed through and emerged from this extraordinary year. #TogetherStrong aptly describes how we progressed through and emerged from this extraordinary year. In 2020, building on five years of double-digit growth, we made a promising start until March, when dental practices closed temporarily or were limited to essential treatment. During the crisis months our focus was on safety, business continu- ity, mitigating financial impacts and helping dentists get back to treating patients. When lock- downs eased, revenue picked up, lifted by pent-up demand. Considering the disruptions and taking 2020 Annual Report the record-level results from 2019 as a comparison, we achieved solid results in 2020. Organic revenue was down 6%, while strong currency headwind widened the gap in Swiss francs to 11% as revenue reached CHF 1.4 billion. Straumann Group Straumann Gilbert Achermann, Chairman of the Board of Directors Guillaume Daniellot, Chief Executive Officer HIGHLIGHTS SHAREHOLDER MANAGEMENT SUSTAINABILITY CORPORATE COMPENSATION FINANCIAL APPENDIX LETTER COMMENTARY REPORT GOVERNANCE REPORT REPORT 8 The pandemic put our original objectives for with further payments expected in the coming improved profitability in 2020 beyond reach. Thanks to our agile response, years. We continued to expand manufacturing However, thanks to rapid mitigation of near-to- capacity (CHF >50 million) which, together with mid-term financial impact, including operating cost we outperformed the market. investments in information technology and other reductions, subsidized working-hour reductions, fixed assets, resulted in capital expenditures of global restructuring and postponed investments, CHF 82 million (CHF 150 million in 2019). Cash we alleviated the heavy pressure on profitability. REBOUNDING ACROSS REGIONS AND BUSINESSES from operating activities amounted to CHF 377 Our core EBITDA, EBIT and net profit margins By year-end, organic growth had returned to all million (CHF 378 million in 2019) and free cash flow reached 29.5%, 23.4% and 18.3% respectively, regions (see p. 35 ff.). APAC rebounded to high-teen reached CHF 295 million (CHF 230 million in 2019). which is very presentable in the circumstances. We growth in Q4 to complete the year almost in line commend our Finance team for their work and for with 2019. EMEA and North America reported mid- MARKETS, ENVIRONMENT – TRENDS securing liquidity to ensure continuity, including single digit declines, while Latin America, facing We estimate that the global market for implant CHF 480 million raised through two straight bonds the biggest challenge, achieved 85% of its 2019 dentistry is worth approximately CHF 4 billion1, to refinance a maturing bond and for general revenue. after contracting by 10–15% due mainly to the corporate purposes. pandemic lockdown. Thanks to our agile response, The value implant, digital and orthodontics busi- we outperformed the market. The drivers of mid- nesses all achieved full-year organic growth, the and long-term market growth remain valid and latter reporting the highest increase. Premium include innovation, the growing and aging popula- We were able to continue implants, our largest revenue driver, were con- tion, awareness of esthetics, increasing availability strained by the pandemic’s impact on predomi- and affordability. investing in innovation nantly premium affluent markets. Notwithstand- to provide faster, better ing, strong sales of innovative products like Our second largest market, clear aligners, is worth Straumann’s BLX implant led to share gains in the approximately CHF 3.5 billion2 (see p. 33 f.) and was treatments. immediacy and other segments. Sales of intraoral growing at 20% prior to COVID-19. In 2020, it was scanners also rose, reflecting the increasing trend almost flat due to the lockdown interruptions.
Load more

Recommended publications
  • Market Notice Date: 14 November 2019 Market Notice Number: 112/2019
    Market Notice Date: 14 November 2019 Market Notice Number: 112/2019 Equiduct Universe Change Please see today's changes below effective 18 November 2019: Trading Reporting MIC Settlement Trading Settlement Tick Size Change/ Security Name ISIN Home Market Symbol Country Currency Currency table Action ABB LTD ABBNz CH0012221716 XSWX EQTB CH CHF CHF ESMA_E Deletion ABB ABBs CH0012221716 XSTO EQTB SE SEK SEK ESMA_E Deletion ADECCO SA ADENz CH0012138605 XSWX EQTC CH CHF CHF ESMA_E Deletion AMS AG AMSz AT0000A18XM4 XSWX EQTC CH CHF CHF ESMA_E Deletion ARYZTA AG ARYNz CH0043238366 XSWX EQTB CH CHF CHF ESMA_E Deletion JULIUS BAER GRUPPE AG BAERz CH0102484968 XSWX EQTC CH CHF CHF ESMA_E Deletion BALOISE-HLDGS BALNz CH0012410517 XSWX EQTC CH CHF CHF ESMA_D Deletion BARRY CALLEBAUT AG BARNz CH0009002962 XSWX EQTC CH CHF CHF ESMA_D Deletion BB BIOTECH BBZAd CH0038389992 XETR EQTB DE EUR EUR ESMA_D Deletion BB BIOTECH BIONz CH0038389992 XSWX EQTB CH CHF CHF ESMA_D Deletion BASILEA PHARMACEUTICA AG BSLNz CH0011432447 XSWX EQTC CH CHF CHF ESMA_D Deletion BUCHER INDUSTRIES BUCNz CH0002432174 XSWX EQTC CH CHF CHF ESMA_D Deletion COMPAGNIE FINANCIERE RICHEMONT CFRz CH0210483332 XSWX EQTC CH CHF CHF ESMA_E Deletion CLARIANT CLNz CH0012142631 XSWX EQTC CH CHF CHF ESMA_E Deletion CEMBRA MONEY BANK AG CMBNz CH0225173167 XSWX EQTC CH CHF CHF ESMA_D Deletion CREDIT SUISSE GROUP AG CSGNz CH0012138530 XSWX EQTC CH CHF CHF ESMA_E Deletion DKSH HOLDING DKSHz CH0126673539 XSWX EQTC CH CHF CHF ESMA_D Deletion DORMA+KABA HOLDING AG DOKAz CH0011795959 XSWX EQTC CH CHF
    [Show full text]
  • Longer Term Investments Medical Devices
    Longer Term Investments Medical devices Chief Investment Office GWM | 11 April 2019 6:53 pm BST Lachlan Towart, Analyst; Stefan R Meyer, Analyst • The aging population and growth of the over-65 age group will create more opportunities for companies selling medical products and devices. • Other drivers of this industry include better penetration in emerging markets due to improved infrastructure, innovative new treatments, increased affordability due to rising per-capita GDP and a growing prevalence of "lifestyle diseases" such as obesity due to urbanization. • We identified five key markets for implantable or wearable devices, including consumer products such as hearing aids, dental implants and corrective lenses. We estimate their total market size at USD 114.8bn with a rate of potential growth in the mid-single digits. • The theme is relatively defensive and should appeal to quality- focused investors. We recommend exposure to it via a diversified portfolio of stocks across our preferred markets and segments. Medical devices can assist in the treatment of many conditions. Some reduce the risk of a treated condition worsening, perhaps as an alternative to drug therapy; others improve users' quality of life or functionality; and still others can solve problems untreatable with drugs. Devices like joint replacements effectively offer permanent long-term solutions (i.e. a cure). Medical devices are primarily used by the over-65 age group, whose growth will outpace the broader population's over the coming decades. Demand is also supported by the rise of "lifestyle diseases" like obesity, itself related to urbanization. The medical device industry has matured, but still represents a substantial opportunity, in our view.
    [Show full text]
  • CS ETF (CH) on SLI Holding AG, Novartis AG and UBS AG
    Simplified Prospectus • October 2011 ® the SLI® as at August 15, 2011 were as follows: Nestlé SA, Roche CS ETF (CH) on SLI Holding AG, Novartis AG and UBS AG. The composition of the index is Subfund of the Umbrella Fund of the Category periodically updated by SIX Swiss Exchange. “Other Funds for Traditional Investments” Risk Profile of the Subfund Simplified Prospectus The value of the Subfund’s investments is governed by the market value of investments at any given time. Depending on the prevailing stock October 2011 market trend and the performance of the stocks held in the portfolio, the net asset value can fluctuate considerably. The possibility of a depreciation Distribution in Switzerland and Liechtenstein in value over longer periods cannot be ruled out. There is no guarantee that the investors will receive a certain return and that they will be able to return their units to the fund management company for redemption at a certain price. When redeeming units, it is possible that an investor will not Note recoup the amount originally invested in the Subfund. This simplified prospectus contains a summary of the key information on CS ETF (CH) on SLI®1 (the “Subfund”). The legal and financial aspects Performance of the Subfund (in %) are governed conclusively by the full sales prospectus with integrated fund (change in the net asset value where distributions are reinvested) contract. These govern, among other things, the rights of the investors, the duties and obligations of the fund management company and the 40.0% custodian bank, and the investment policy of the Fund.
    [Show full text]
  • Full Portfolio Holdings
    Hartford Multifactor International Fund Full Portfolio Holdings* as of August 31, 2021 % of Security Coupon Maturity Shares/Par Market Value Net Assets Merck KGaA 0.000 152 36,115 0.982 Kuehne + Nagel International AG 0.000 96 35,085 0.954 Novo Nordisk A/S 0.000 333 33,337 0.906 Koninklijke Ahold Delhaize N.V. 0.000 938 31,646 0.860 Investor AB 0.000 1,268 30,329 0.824 Roche Holding AG 0.000 74 29,715 0.808 WM Morrison Supermarkets plc 0.000 6,781 26,972 0.733 Wesfarmers Ltd. 0.000 577 25,201 0.685 Bouygues S.A. 0.000 595 24,915 0.677 Swisscom AG 0.000 42 24,651 0.670 Loblaw Cos., Ltd. 0.000 347 24,448 0.665 Mineral Resources Ltd. 0.000 596 23,709 0.644 Royal Bank of Canada 0.000 228 23,421 0.637 Bridgestone Corp. 0.000 500 23,017 0.626 BlueScope Steel Ltd. 0.000 1,255 22,944 0.624 Yangzijiang Shipbuilding Holdings Ltd. 0.000 18,600 22,650 0.616 BCE, Inc. 0.000 427 22,270 0.605 Fortescue Metals Group Ltd. 0.000 1,440 21,953 0.597 NN Group N.V. 0.000 411 21,320 0.579 Electricite de France S.A. 0.000 1,560 21,157 0.575 Royal Mail plc 0.000 3,051 20,780 0.565 Sonic Healthcare Ltd. 0.000 643 20,357 0.553 Rio Tinto plc 0.000 271 20,050 0.545 Coloplast A/S 0.000 113 19,578 0.532 Admiral Group plc 0.000 394 19,576 0.532 Swiss Life Holding AG 0.000 37 19,285 0.524 Dexus 0.000 2,432 18,926 0.514 Kesko Oyj 0.000 457 18,910 0.514 Woolworths Group Ltd.
    [Show full text]
  • Julius Baer Multicooperation Annual Report 2005 As at June 30, 2005 (Audited)
    Julius Baer Multicooperation Annual Report 2005 as at June 30, 2005 (audited) Subscriptions are only valid if made on the basis of the current Prospectus, the latest Annual Report and the latest Semi-Annual Report if published thereafter. The Articles of Association, the valid Prospectus and the Annual and Semi-Annual Reports may be obtained free of charge at the representative in Switzerland and the respective paying agent. Only the German version of the present Annual Report has been reviewed by the independent auditor. Consequently, the independent auditor's report only refers to the German version of the Report; other versions result from a conscientious translation made under the responsibility of the Board. In case of differences between the German version and the translation, the German version shall be the authentic text. AN INVESTMENT FUND DOMICILED IN LUXEMBOURG Representative in Switzerland: Julius Baer Investment Funds Services Ltd., Zurich Paying agent in Switzerland: Bank Julius Bär & Co. AG, Bahnhofstrasse 36, Postfach, CH - 8010 Zurich Paying agent in Germany: Bank Julius Bär (Deutschland) AG, Messe Turm, Friedrich-Ebert-Anlage 49, Postfach 15 01 52, D - 60061 Frankfurt on the Main Paying agent in Austria: Erste Bank der oesterreichischen Sparkassen AG, Graben 21, A - 1010 Vienna Contents Page Organisation and Management 4 Independent Auditor's Report 5 Notes to the Financial Statements 6 Julius Baer Multicooperation (Umbrella Fund) MCOO Julius Baer Multicooperation - Emerging Markets Value Stock Fund HESF Julius Baer Multicooperation
    [Show full text]
  • Gateway to Professional Learning Dental Service Organization Global
    Gateway to professional learning More than creating smiles Restoring confidence Dental Service Organization Global Courses 2021 2 Sharpen your skills at every level of competence When it comes to training, the expectations of dental professionals today are higher than ever before. Every dental professional is unique and benefits from individual training. Straumann® stands for variety and innovation. This means that we offer the perfect life-long professional education in more than 70 countries, addressing the needs of dentists, dental technicians and dental assistants throughout their career. Continuous professional growth is of paramount importance to dental professionals. Our aim is to provide a comprehensive, lifelong education and training program on surgical and restorative procedures with the latest technologies available at all levels of complexity. This means we offer educational programs ranging from the fundamentals of dental implantology to very complex procedures. This ensures that you are equipped to grow professionally and personally at every stage of your professional life. We invite you to an educational journey with us! The Straumann Group Dental Service Organization Team Find us at: [email protected] 3 Educational Pathways for professional growth – for the entire dental team Get started Get experience LEVEL 1 LEVEL 2 LEVEL 3 New to Implantology: These These courses allow you to These courses will enable you to courses will allow you to perform develop your existing experience treat challenging situations using surgical and prosthetic procedures in implant dentistry. advanced treatment planning and in cases that are less complex and complex surgical and prosthetic have predictable esthetic and Courses include: procedures. It requires significant functional outcomes.
    [Show full text]
  • First-Quarter 2021 Report – Media Release
    First-quarter 2021 report – Media Release Straumann Group reports very strong first-quarter sales results accelerated by product launches and consumer focus on oral health . Record quarterly revenue of CHF 470 million, 34% organic growth compared to previous year which was already impacted by the pandemic . Acquisition effect of 2% due to DrSmile . Recent investments and product launches driving growth, performance lifted by strong consumer focus on oral health . Strong organic double-digit growth in all regions; contributions led by the largest regions EMEA and North America . Investment of CHF 170 million by 2029 in China Campus to support future growth . Full-year 2021 outlook raised to organic revenue growth in the mid-to-high twenties percentage range expecting an improvement in profitability (core EBIT margin) compared to 2020 REVENUE BY REGION Q1 2021 Q1 2020 (in CHF million) Europe, Middle East & Africa (EMEA) 214.3 162.2 Change in CHF in % +32.1 0.9 Change in local currencies in % +33.1 7.5 Change organic1 in % +27.0 0.1 % of Group total 45.6 45.4 North America (NAM) 138.0 115.7 Change in CHF in % +19.4 4.9 Change in local currencies in % +27.0 7.9 Change organic1 in % +27.0 7.7 % of Group total 29.4 32.4 Asia Pacific 92.3 53.5 Change in CHF in % +72.4 -25.5 Change in local currencies in % +74.4 -21.7 Change organic1 in % +74.4 -22.1 % of Group total 19.6 15.0 Latin America 25.2 26.0 Change in CHF in % -3.1 -12.0 Change in local currencies in % +23.8 7.3 Change organic1 in % +23.8 7.2 % of Group total 5.4 7.3 GROUP 469.8 357.3 Change in CHF in % +31.5 -4.0 Change in local currencies in % +37.0 1.9 Change organic1 in % +34.0 -1.4 1 Excluding the effects of currencies and acquisitions Page 1/6 Basel, April 29, 2021: The Straumann Group made an exceptional start to 2021 and the solid growth trend experienced in the second half of 2020 accelerated.
    [Show full text]
  • Survival and Complications of Zygomatic Implants: an Updated Systematic Review
    Accepted Manuscript Survival and complications of zygomatic implants: an updated systematic review Bruno Ramos Chrcanovic, DDS, MSc, PhD student, Tomas Albrektsson, MD, PhD, Ann Wennerberg, DDS, PhD PII: S0278-2391(16)30446-3 DOI: 10.1016/j.joms.2016.06.166 Reference: YJOMS 57322 To appear in: Journal of Oral and Maxillofacial Surgery Received Date: 21 January 2016 Revised Date: 1 June 2016 Accepted Date: 8 June 2016 Please cite this article as: Chrcanovic BR, Albrektsson T, Wennerberg A, Survival and complications of zygomatic implants: an updated systematic review, Journal of Oral and Maxillofacial Surgery (2016), doi: 10.1016/j.joms.2016.06.166. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. ACCEPTED MANUSCRIPT Survival and complications of zygomatic implants: an updated systematic review Bruno Ramos Chrcanovic 1* Tomas Albrektsson 2 Ann Wennerberg 3 1 DDS, MSc, PhD student, Department of Prosthodontics, Faculty of Odontology, Malmö University, Malmö, Sweden 2 MD, PhD, Retired Professor and former Head of the Department of Biomaterials, Göteborg University, Göteborg, Sweden; Guest Professor of the Department of Prosthodontics, Faculty of Odontology, Malmö University, Malmö, Sweden 3 DDS, PhD, Professor and Head of the Department of Prosthodontics, Faculty of Odontology, Malmö University, Malmö, Sweden MANUSCRIPT * Corresponding author: Bruno Ramos Chrcanovic, Department of Prosthodontics, Faculty of Odontology, Malmö University, Carl Gustafs väg 34, SE-205 06, Malmö, Sweden.
    [Show full text]
  • Counting Caries
    Volume 57 Number 3 June/July 2011 Journal of the Irish Dental Association Iris Cumainn Déadach na hÉireann Counting caries An audit of the caries status of patients about to start orthodontic treatment Contents JOURNAL OF THE IRISH DENTAL ASSOCIATION IDA PRESIDENT Dr Conor McAlister The Journal of the Irish Dental Association: - is the only dental publication produced in Ireland; IDA CHIEF EXECUTIVE Fintan Hourihan - is Irish dentists' own Journal of record. JOURNAL CO-ORDINATOR Fionnuala O’Brien 125 EDITORIAL EDITOR Professor Leo F.A. Stassen 126 PRESIDENT’S NEWS FRCS(Ed), FDSRCS, MA, FTCD, FFSEM(UK) FFDRCSI Setting priorities for the year ahead DEPUTY EDITOR 127 LETTERS TO THE EDITOR Dr Dermot Canavan BDentSc, MGDS(Edin), MS(UCalif) 128 IDA NEWS EDITORIAL BOARD Association meets Ministers … Volunteer Professor Finbarr Allen for the Ploughing … Association BDS PhD MSc FDS FDS(Rest Dent) RCPS highlights rise in dental ill health …Quiz FFDRCSI 134 BOOK REVIEW Dr Tom Feeney Oral and Intravenous Bisphosphonate- BDS Dip Cl Dent(TCD) FICD induced Osteonecrosis of the Jaws Obituary 130 Dr Michael Fenlon The sad passing of a well respected former President PhD BDentSc MA FDS MGDS 136 BUSINESS NEWS Industry news for dentists Dr David Hussey BDS PhD FHEA FDSRCPS FFDRCSI FDSRCS 140 EUROPE Dr Carmel Parnell Modernising the Professional BDentSc, MPH Qualifications Directive Dr Ioannis Polyzois 142 DECONTAMINATION FEATURE DMD, PhD, MDentCh, MMedSc Three steps to decontamination Dr Ciara Scott heaven BDS MFD MDentCh MOrth FFD (RCSI) Dr Seamus Sharkey
    [Show full text]
  • Pikos Symposium 2019
    Pikos Symposium 2019 Dear Colleague, I want to personally invite you to attend the Pikos Institute sponsored Full Arch Immediate Reconstruction Symposium 2019. This one of a kind program will feature 15 of the world’s Master Clinicians as they share their surgical and restorative protocols for full arch immediate reconstruction in a most unique mode. In keeping with the Pikos Symposium format, each speaker and team will have two hours to present their material including 20 minutes of direct Q & A with all audience questions texted during the speaker’s presentation. This format will allow each speaker ample time to develop their respective topic, as well as to provide for direct audience participation. This symposium is for both entry level and advanced level clinicians who desire to advance their knowledge of clinically relevant and evidence based state of the art surgical and prosthetic strategies for full arch immediate reconstruction. It will cover the entire spectrum of both the scientific and clinical elements of this most relevant area of implant rehabilitation from freehand analog based protocols to partially and fully guided immediate full arch reconstruction protocols. Pikos Symposium 2019 will include, but not be limited to, the following topics: • Indications and contraindications for full arch immediate reconstruction of edentulous and soon to be edentulous arches • Comprehensive diagnostic criteria for maxillary and mandibular full arch immediate reconstruction for edentulous and terminal dentate arches • Treatment planning
    [Show full text]
  • Ishares SMIM® ETF (CH)
    Creatiedatum 26 sep 2021 iShares SMIM® ETF (CH) Morningstar Analyst Rating™ Morningstar Categorie Index Benchmark van het fonds Morningstar Rating™ Morningstar Categorie™ MSCI Switzerland Small Cap NR SIX SMI Mid TR CHF QQQ Aandelen Zwitserland Small/Mid CHF Cap Wordt gebruikt in dit rapport als index 22.5 Beleggingsdoelstelling Groei van 10000 (EUR) 20.0 Fonds The Fund aims to achieve a return on your investment 17.5 Index which reflects the return of the Swiss Market Index Mid 15.0 Categorie (SMIM®), the Fund's benchmark index. The benchmark 12.5 is weighted in accordance with the free-float value of 10.0K Swiss equities with an average market capitalization. 2016 2017 2018 2019 2020 08/21 Rendement It comprises the 30 largest, most liquid stocks on the Swiss equity market that are not included in the SMI®. 7.80 20.94 -14.18 39.86 5.73 24.44 Fonds The index is calculated on a real-time basis in CHF. -4.88 -3.57 8.55 6.10 -7.41 1.49 +/- Index -5.01 2.62 1.22 7.68 -4.43 0.43 +/- Categorie - - - - - - Percentiel Score Risicomaatstaven Rendementen (24 sep 2021) Rend % +/-Idx +/-Cat Kwartaalrendementen 1e kw 2e kw 3e kw 4e kw Alpha 0.64 Sharpe Ratio 0.81 3 Maanden 2.82 -5.79 -2.87 2021 6.42 10.54 - - Beta 0.97 Std Deviatie 17.18 6 Maanden 15.68 -1.12 -2.47 2020 -18.87 13.98 4.79 9.11 R-kwadraat 90.70 3-jr Risico Bov gem 1 jaar 36.75 -0.79 0.35 2019 16.62 7.47 4.33 6.96 Informatie Ratio 0.03 5-jr Risico Bov gem 3 jr gean.
    [Show full text]
  • Straumann Group 2020 Full-Year Results
    #TogetherStrong Virtual2020 full-year townhall results meeting conference Basel, 16 February 2021 1 Disclaimer This presentation contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Straumann Group to differ materially from those expressed or implied in this presentation. The Group is providing the information in this presentation as of this date and does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise. The availability and indications/claims of the products illustrated and mentioned in this presentation may vary according to country. 2 2 FY 2020, Straumann Group 1 2/15/2021 9:46 PM Agenda Full-year highlights Guillaume Daniellot Business & regional review Peter Hackel Recent achievements & strategy in action Guillaume Daniellot Outlook 2021 Guillaume Daniellot Guillaume Daniellot Q&A and upcoming events Peter Hackel 3 Full-year highlights Guillaume Daniellot, CEO 4 FY 2020, Straumann Group 2 A challenging year with solid results returning to organic growth in the second half of 2020 REVENUE ORGANIC GROWTH1 CORE EBIT MARGIN2 CHF 1.4bn -6% 23.4% -11% vs 2019 +8% organic growth1 in Q4 IFRS EBIT margin: 11% CUSTOMER FOCUS EXPANSION OUTLOOK3 Immediacy DrSmile Further share gains Straumann BLX, Zygoma, TLX Entering into Direct-to-Consumer 2021: high-single-digit percentage marketing with doctor-led treatment organic revenue growth, core EBIT expected to improve vs 2020 1 Organic growth = excluding effects of currencies and business combinations 2 Core figures exclude one-time M&A effects, exceptional 5 pension-plan items, restructuring and non-recurring litigation expenses, amortization and impairment of goodwill and acquisition related intangible assets.
    [Show full text]